Nephrogenic systemic fibrosis: a concise review for cardiologists.
Nephrogenic systemic fibrosis is a recently recognized disease entity that is potentially debilitating. The exact pathogenesis of nephrogenic systemic fibrosis is unclear, but the disease has been linked with the use of gadolinium-based contrast agents, predominantly in patients with acute renal failure or end-stage renal disease. Consequent to increased physician awareness of this link, the incidence of nephrogenic systemic fibrosis has begun to decrease. The aims of this review are to provide a concise summary of the approved gadolinium-based contrast agents available in the United States, to discuss the postulated pathogenesis of nephrogenic systemic fibrosis, to describe the clinical features of the disease, and to provide broad recommendations for gadolinium-based contrast agent use.
Department of Radiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA. bcheong@sleh.com
Benjamin Y C
BY
Cheong
Raja
R
Muthupillai
D058186:Acute Kidney Injury / Q000150:complications; D002318:Cardiovascular Diseases / Q000175:diagnosis*; D003287:Contrast Media / Q000009:adverse effects*; D005682:Gadolinium / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008279:Magnetic Resonance Imaging / Q000009:adverse effects*; D054989:Nephrogenic Fibrosing Dermopathy / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors
D003287:Contrast Media; D005682:Gadolinium